एवानाफिल और ड्यूटास्टेराइड और टैम्सुलोसिन का इंटरैक्शन

Exercise caution with concomitant use of phosphodiesterase-5 (PDE-5) inhibitors, as this may increase the risk of hypotension.

Phosphodiesterase-5 (PDE-5) Inhibitors Caution is advised when alpha-adrenergic–antagonist-containing products, including JALYN, are coadministered with PDE-5 inhibitors.

Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure.

• Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 )

Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Consideration should be given to the following: • Patients should be stable on alpha-blocker therapy prior to initiating treatment with a PDE5 inhibitor.

Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.

• In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose (Avanafil 50 mg).